Immunic price target lowered to $19 from $26 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Immunic (IMUX) to $19 from $26 but keeps a Buy rating on the shares after its Q1 earnings miss. Investors continue to view Immunic through the lens of RMS though the firm believes the company’s solidified cash position strongly positions Immunic to initiate a Phase 3 study in PPMS in the second half of 2026, the analyst tells investors in a research note.